BeOne Medicines Ltd. (ONC) Q4 FY25 Earnings Call

Brukinza leadership, 2026 growth guidance, and expanding pipeline support continued commercial and R&D momentum.

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-02-27
Length67 minutes
EPS$0.58
Revenue$1.5B

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Read the full Q4 FY25 earnings call transcript

All ONC earnings · Back to ONC overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.